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Abstract
Background: Genomic characterization of prostate cancer (PCa) biopsies may
improve criteria for the selection of patients suitable for active surveillance (AS).
Objective: To identify somatic genomic aberrations associated with adverse out-
come as AS protocol exclusion indicators.
Design, setting and participants: Whole-exome sequencing proﬁles were generat-
ed for Gleason score (GS) = 3 + 3 biopsies obtained from 54 PCa patients enrolled in
two AS protocols. Patients were selected as representative of a nonindolent popu-
lation, consisting of 27 patients who dropped out from AS due to upgrading
(ie, ﬁnding of GS > 3 + 3 at a follow-up biopsy) within 2 yr, and a potentially
indolent population, consisting of 27 patients in AS for 4 yr without any evidence
of reclassiﬁcation.
Outcomemeasurements and statistical analysis: The genomic alteration landscape
of core biopsies was analyzed using an integrated computational pipeline and
correlated with patient reclassiﬁcation due to upgrading.
Results and limitations: Of all the GS = 3 + 3 biopsies of the study cohort, 34%
showed clear evidence of somatic copy number aberrations along the genome. Of
these, 39% came from the potentially indolent and 61% from the nonindolent
population. Single-nucleotide variants demonstrated low allelic fractions and
included a common F133C mutation in the SPOP gene. The minimally altered
genomic landscape of the study cohort presented a distinct set of monoallelic
ondeletions, including1 These authors contributed equally to this work and should be regarded as joint ﬁrst authors.
2 These authors contributed equally to this work and should be regarded as joint last authors.
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were observed in both AS patient populations. Concerning lesions typically
associated with adverse outcome, PTEN deletions and MYC ampliﬁcation,
though observed in a small number of cases, were detected exclusively or
preferentially, respectively, in nonindolent patients. Such molecular ﬁndings
were conﬁrmed by immunohistochemistry on the same tissue blocks. The small
sample size and the retrospective nature of the analysis represent the main
study limitations.
Conclusions: Genomic features enriched in aggressive tumors can be detected
in GS = 3 + 3 core biopsies of AS patients.
Patient summary: PTEN and MYC alterations at the time of diagnosis would
deserve investigation in larger cohorts of AS patients to assess their potential as
biomarkers for a more precise/earlier identiﬁcation of patients at risk of
reclassiﬁcation.
© 2018 The Author(s). Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Prostate cancer (PCa) is the second most common tumor
and the sixth leading cause of cancer-related mortality
among men worldwide [1]. Screening based on prostate-
specific antigen (PSA) levels resulted in amarked increase in
the number of patientswith newly diagnosed PCa, including
a large proportion with low-grade, potentially indolent
cancers that are likely to remain clinically insignificant.
Overtreatment is a well-documented consequence of
overdiagnosis leading to patient exposure to treatment
morbidities, thus negatively affecting quality of life [2].
Active surveillance (AS) evolved as alternative to radical
treatment for potentially indolent PCa with the aim toTable 1 – Inclusion criteria, follow-up schedule, and indications for di
Nazionale Tumori, Milan
SAINT
Inclusion criteria
PSA 10 ng/ml
Clinical stage T1c or T2a; T1b if cancer 0.5 cm
biopsies of the peripheral zone
GS 3 + 3
Number of positive cores 20% of all cores until December 2
25% of all cores since December
PSA density –
Core involvement 50% of core involvement
Follow-up schedule
PSA measurement Every 3 mo
Digital rectal examination (DRE) Every 6 mo
Re-biopsy Year 1
Year 2
Then every subsequent 2 yr
Indications for AS discontinuation PSA doubling time (DT) <3 yr;
clinical stage >T2c as determined
disease upgrading (GS > 6) or upsi
positive cores or tumor involveme
core exceeding the criteria for AS)
SAINT = Sorveglianza Attiva Istituto Nazionale Tumori; PRIAS = Prostate Cancer
surveillance.reduce overtreatment, without compromising opportu-
nities for cure. Existing guidelines predominantly state
that patients presenting with biopsy Gleason score (GS) = 3
+ 3, minimal cancer volume, clinical stage T2, and PSA
levels <10 ng/ml are suitable for AS. Patients are strictly
monitored and curative treatments are avoided or deferred
until evidence of more aggressive PCa is seen [3]. Unfortu-
nately, current inclusion criteria are suboptimal and about
25% patients discontinue AS for PCa reclassification, mainly
upgrading (GS > 3 + 3) at the re-biopsy [3–5]. To what
extent tumor reclassification reflects progression from low-
to high-grade or incomplete sampling on the initial biopsy
(ie, patients with apparently low-risk disease may harbor
occult higher-grade cancer) remains unclear.scontinuation of the two active surveillance protocols at Istituto
PRIAS
<10 ng/ml
3 and negative T2c
3 + 3 or
3 + 4 in age >70 yr, tumor involving <10% core
length
012;
2012
2 or
15% of all cores in case of saturation biopsy
(>20 cores) with a maximum of 4
<0.2 ng/ml/cm3
–
Every 3 mo
Every 6 mo
1, 4, and 7 yr after the diagnostic biopsy
by DRE;
zing (number of
nt per biopsy
at re-biopsy
PSA DT <3 yr;
clinical stage >T2c at DRE;
>2 positive cores (upsizing), or GS > 6
(upgrading) at re-biopsy
Research International: Active Surveillance; GS = Gleason score; AS = active
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lesions and relevant breakpoints from intrapatient grade
pattern 3 (G3) and G4 tumors suggested that a subset of G3
tumors may progress to G4 or emerge from a common
precursor, andmay bemolecularly distinct from isolated G3
tumors not associated with higher grades [6]. PTEN protein
loss and chromosome 8 alterations, including 8q (MYC) gain
and 8p (LPL) loss, in G3 cancers were reported as associated
to the presence of unsampled G4 lesions [7]. Further, tumors
morphologically appearing as G3 in biopsy but character-
ized by PTEN protein loss demonstrated an increased rate of
upgrading at prostatectomy than those retaining PTEN
[8]. Recently, whole-exome sequencing (WES) of adjacent
G3 and G4 tumors in radical prostatectomies revealed that
the two entities shared multiple mutations and somatic
copy number alterations, with G3 tumors harboring
oncogenic lesions (eg, losses of PTEN or NKX3-1 tumor
suppressors) [9]. Remarkably, the finding that G4-associat-[(Fig._1)TD$FIG]
Fig. 1 – Schematic summary of study design. A total of 54 PCa patients prospec
a nonindolent (n = 27) or of a potentially indolent (n = 27) populations. Fourteen
enrolled in PRIAS, with no statistically significant differences in the rate of ind
from all patients. For the nonindolent population, an additional GS = 3 + 3 core
from dropout biopsies of five patients. DNA extracted from formalin-fixed para
evaluated prior to preparation of sequencing libraries via HaloPlex Exome Targ
available for 27 GS = 3 + 3 biopsies and 6 GS = 3 + 4 biopsies from 25 nonindolen
patients. Generated WES data were preprocessed by following well-established
in order to detect high-confidence somatic copy number alterations (SCNAs) aned G3 tumors retain their indolent-appearing morphology
despite the acquisition of multiple genomic alterations
highlights the need for validated molecular markers to be
detected in diagnostic biopsies to improve the selection of
patients suitable for AS. So far, few studies queried AS
patients’ diagnostic biopsies for selected protein expres-
sion. ERG expression identified patients with an increased
risk of reclassification during AS [10] and PTEN protein loss,
but not ERG expression, was significantly associated with
upgrading at the re-biopsy and adverse histopathology in
radical prostatectomy [11]. Altogether, these studies sup-
port the molecular investigation of diagnostic biopsies to
improve criteria of AS enrollment.
Here, we performed a comprehensive genomic exercise
by retrospectively analyzing the exome of GS = 3 + 3 core
biopsies prospectively and consecutively collected from
low-risk PCa patients enrolled on AS at Fondazione IRCCS
Istituto Nazionale dei Tumori (INT), Milan, Italy.tively enrolled in AS protocols were selected as representative of either
of 54 patients were enrolled in the SAINT protocol, while 40 of 54 were
olent/nonindolent patients (p = 0.063). GS = 3 + 3 cores were obtained
was obtained from two patients, and six GS = 3 + 4 cores were obtained
ffin-embedded (FFPE) biopsies and white blood cells was quantified and
et Enrichment System. As a result, high-quality DNA material was
t patients and for 26 GS = 3 + 3 biopsies from 26 potentially indolent
computational pipelines and analyzed by applying strict quality criteria
d somatic single nucleotide variants (SNVs).
Table 2 – Clinical and pathological characteristics for the whole
population and for the two separated cohorts of “nonindolent”
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At INT, low-risk PCa patients are proposed for AS provided they fulﬁll the
enrolment criteria deﬁned by either the single-center SAINT (Sorve-
glianza Attiva Istituto Nazionale Tumori) protocol, established in March
2005 [12], or the international PRIAS (Prostate Cancer Research
International: Active Surveillance) protocol, coordinated by Erasmus
University Medical Center (Rotterdam, The Netherlands) [4] and joined
in November 2007. Details of the inclusion criteria, follow-up schedules,
and indications for discontinuation are reported in Table 1. In this study,
two sets of AS patients were considered. The ﬁrst set, referred to as the
nonindolent population, includes patients who dropped out from AS due
to upgrading (ie, ﬁnding of GS > 3 + 3 at a re-biopsy) within 2 yr from
inclusion. Patients who dropped out for other reasons (eg, upsizing, PSA
doubling time <3 yr) were not included. The second set, referred to as
potentially indolent population, includes patients on AS for at least 4 yr
(ie, no evidence of tumor reclassiﬁcation). Figure 1 reports the design of
the study, which was approved by the Institutional Ethical Committee.
All patients gave written informed consent to donate biological material
for research purposes. Original grading of study biopsies was assigned
using the ISUP 2005 guidelines. A recent revision by the study
pathologist (M.C.) showed that all GS = 3 + 3 cores can be attributed
to new prognostic grade group 1 (PGG1) and GS = 3 + 4 cores to new
PGG2, according to the Consensus Conference ISUP 2014 criteria.
Details on sample processing, WES, computational analyses, and
immunohistochemistry are reported in the Supplementary methods.population and “potentially indolent (indolent)” population
Variable
(at diagnosis)
Median Interquartile
range
p value
(Mann–Whitney
test)
Positive cores (n)
Nonindolent 1 1–2 0.06
Indolent 1 1–1
All patients 1 1–2
Total cores (n)
Nonindolent 12 10–14 0.53
Indolent 12 10–15
All patients 12 10–14
Positive cores (%)
Nonindolent 13 8–16 0.06
Indolent 10 7–12
All patients 10 8–14
Cores with Pca (max %)
Nonindolent 18 6–34 0.17
Indolent 10 5–25
All patients 10 5–30
Age (yr)
Nonindolent 69 70–72 0.76
Indolent 67 64–72
All patients 67.5 63–72
PSA (ng/ml)
Nonindolent 5.4 4.5–6.7 0.83
Indolent 5.6 4.4–6.9
All patients 5.4 4.5–6.7
Prostate volume (cm3)
Nonindolent 36 30–46 0.01
Indolent 57 40–102
All patients 41 35–50
PSA density (ng/ml/cm3)
Nonindolent 0.15 0.13–0.18 0.06
Indolent 0.11 0.086–0.17
All patients 0.13 0.094–0.17
Clinical stage
Nonindolent T1c, 85.2% T2a, 14.8% 0.38a
Indolent T1c, 92.6% T2a, 7.4%
All patients T1c, 88.9% T2a, 11.1%
a p value from z-test for proportions.3. Results
3.1. Clinical characteristics of AS patients amenable to WES
Fifty-four patients were included in the study cohort
including 27 from the nonindolent and 27 from the
potentially indolent population. Table 2 reports the distri-
bution of clinical–pathological features at diagnosis. No
statistically significant differences were found between the
two patient populations except for prostate volume, in
accordancewith previously published results on association
between volume and the probability of upgrading at re-
biopsies [12]. No statistically significant differences were
observed between patients from the two AS protocols,
except for PSA and PSA density, which were higher in SAINT
due to lack of criteria on PSA density.
Initial quantification tests showed that nearly one whole
formalin-fixed paraffin-embedded (FFPE) GS = 3 + 3 biopsy
was necessary to obtain sufficient DNA for WES library
preparation. In compliance with the ethical and legal issues
of preserving informative diagnostic material for each
patient, we could select only patients with at least two
positive cores at the elected biopsy (note that approx. 70% of
patients have only one positive core at diagnosis).
Therefore, for the nonindolent population, GS = 3 + 3/PGG1
cores were obtained from the dropout biopsy in 25/27
cases; the diagnostic biopsy or 1-yr re-biopsy were used for
one patient each. Six GS = 3 + 4/PGG2 cores (referred towith
_H) were obtained from dropout biopsies of five patients
and analyzed for comparative purposes. An additional
GS = 3 + 3/PGG1 core (referred to with _sec) was analyzed
for two patients. For the potentially indolent population,
GS = 3 + 3 cores from the 1-yr re-biopsy were used for13 patients, from the 2-yr biopsy for 6 patients, from the 3-
yr biopsy for 3 patients, and from the 4-yr biopsy for
5 patients (Supplementary Fig.1A). To maximize the chance
to obtain informative data from such challenging speci-
mens, the core with maximum length and percentage of
cancer cells was selected for genomic characterization.
High-quality DNA suitable for WES library preparation was
obtained from 53 of 56 (94.6%) GS = 3 + 3/PGG1 and from
6 of 6 (100%) GS = 3 + 4/PGG2 FFPE biopsies (and from all
matched blood samples) (Fig. 1).
3.2. Overall genomics of GS = 3 + 3/PGG1 biopsies from AS
patients
Exome sequencing data were successfully generated on a
40-Mb target with >180 M reads per tumor sample and
85 M per matched normal sample, resulting in >240 and
100 depth of coverage, respectively (Supplementary
Fig. 2A and 2B and Supplementary Table 1). Genetic-based
tests confirmed tumor/normal pairs [13] (Supplementary
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(Supplementary Fig. 1C) [14]. Upon data segmentation, we
computationally assessed tumor ploidy and purity using
CLONET [15], which exploits informative SNPs and copy
number data. Of all GS = 3 + 3/PGG1 biopsies, 34% (n = 18/
53) showed clear evidence of somatic copy number
aberrations (SCNAs) along the genome, 39% of which came
from potentially indolent (n = 7/18) and 61% from
nonindolent (n = 11/18) patients (Fig. 2A). The tumors
showed diploid features and median cellularity (tumor
purity) equal to 31% and 39%, respectively, with an outlier
sample with 0.8 tumor purity (Fig. 2B and Supplementary
Table 2). The fraction of the genome affected by SCNAs (copy
number altered fraction, CNAF) did not differ significantly
between the two populations with median values of 4% and
a slightly longer upper tail in the nonindolent group (Fig. 2B
and Supplementary Table 2). Detected single-nucleotide
variants (SNVs) included a common F133Cmutation in SPOP
(Supplementary Fig. 3) and demonstrated low allelic
fractions in agreement with previous studies of localized
PCa [15]. No significant differences were detected between
the two groups (Supplementary Fig. 4). No statistically
significant differences were observed when testing dis-
tributions of tumor content, ploidy, CNAF, and mutational[(Fig._2)TD$FIG]
Fig. 2 – Whole-exome characterization of clinical biopsies of AS patients. (A) P
nondetectable somatic copy number alterations (SCNAs) and stratified by poten
distributions of tumor ploidy, tumor purity, and fraction of genome affected b
patients; p values from Wilcoxon tests. (C) Frequency of gains and losses in qu
study cohort.load in potentially indolent and nonindolent populations
stratified by AS protocol.
In line with low-grade PCa genomic profiles from
prostatectomy series [16,17], theminimally altered genomic
landscape of our cohort presents a distinct set of mono-
allelic deletions, including on 8p,13q,16q, and 21q, and rare
amplifications of 8q (Fig. 2C and Supplementary Fig. 5).
Interestingly, those lesions are observed in both popula-
tions. Overall, the most common lesion across the whole
dataset spans NKX3-1 (8p) and was present in >50% of the
analyzed tumors (Fig. 3A).
3.3. Key lesions detected in GS = 3 + 3/PGG1 biopsies
To specifically assess whether the genomics of tumor
biopsies from AS patients could inform on lesions typically
associated with adverse outcome, we focused on genomic
events in PTEN and MYC and on two common genomic
events as loss of NKX3-1 and interstitial deletion between
TMPRSS2 and ERG [16] (Fig. 3A). Whereas no PTEN
deletions were evident in the potentially indolent set,
one patient from the nonindolent population (n = 1/10,
10%) harbored a deletion of PTEN in both GS = 3 + 3 biop-
sies. Of note, three patients (one potentially indolent andie chart reporting the number of samples with detectable and
tially indolent and nonindolent patients. (B) From left to right,
y SCNAs are compared between potentially indolent and nonindolent
eried genomes, color coded by population, which shows SCNAs in the
[(Fig._3)TD$FIG]
Fig. 3 – Assessment of key lesions in GS = 3 + 3 biopsies. (A) Heatmap of somatic copy number alteration (SCNA) status of NKX3-1 (8p), MYC (8q), PTEN,
and interstitial deletion between TMPRSS2 and ERG (21q22.2, ERG-TMPRSS2) in potentially indolent (n = 7) and nonindolent (n = 11) samples. (B) Allele-
specific copy number analysis by CLONET of three nonindolent patient samples, 1T, 6T, and 17T, shows distinct clusters of nonaberrant diploid
segments (allele A = 1, allele B = 1) together with clonal hemizygous deletions (allele A = 1, allele B = 0). Allele-specific copy number gain (two to three
extra copies of allele A) for a set of genes including MYC (8q) is observed for patient 6T. (C) Immunohistochemistry of GS = 3 + 3 biopsies from two
patients. Top, sample 6T: photomicrograph (T200 magnification) shows positive c-Myc staining in most tumor cells. Bottom, sample 17T:
photomicrograph (T200 magnification) demonstrates PTEN protein loss in tumor cells with preservation of PTEN staining in adjacent normal tissue.
(D) Frequency of genomic aberration of NKX3-1, MYC, PTEN, and ERG-TMPRSS2 genes in this study and in a collection of 426 clinically localized PCas
treated by radical prostatectomy and stratified into five prognostic grading groups (PGGs) ranging from 1 to 5 defined as Gleason grades  6, 3 + 4, 4
+ 3, 8, and > 8, respectively.
E U RO P E AN U RO L OGY ONCO L OGY 2 ( 2 019 ) 2 7 7 – 2 8 5282two nonindolent) (n = 3/18, 17%) demonstrated clear
amplification ofMYC. Allele-specific copy number analysis
(Supplementary Fig. 6) indicated up to four DNA copies of
MYC in sample 6T (Fig. 3B), which was confirmed by
immunohistochemistry, showing high although heteroge-
neous c-Myc staining, with some tumor cells completely
negative and some with high expression within the same
gland (Fig. 3C). The same analysis confirmed segregation
of PTEN deletion signal in clonal monoallelic clusters with
NKX3-1 deletions in sample 17T (Fig. 3B). This finding was
paralleled by in situ evidence of PTEN protein loss in tumor
glands, with preservation of positive staining in adjacent
normal cells (Fig. 3C).
Next, we compared the study incidence of these key
lesions with what was previously observed in prostatec-tomy series stratifying the data by PGG [18]. Despite the
relatively small size of the current study, observed
frequencies are comparable to those of PGG1 and/or
PGG2, which group patients with GS = 3 + 3 and 3 + 4,
respectively (Fig. 3D).
3.4. Comparative analysis of upgrading biopsies
Upgrading biopsies (GS = 3 + 4/PGG2) were considered for
comparative analysis for a subset of nonindolent patients. Of
those, 67% (n = 4/6) demonstrated clear somatic copy
number signal and data were retained for allele-specific
SCNA profiles. Figure 4 reports biopsy sites and allele-
specific results for the three individuals. One patient
(patient 4) showed fairly identical profiles between the
[(Fig._4)TD$FIG]
Fig. 4 – Comparison between GS = 3 + 3 (_T and _Tsec) and GS = 3 + 4 (_H) biopsies in 3 nonindolent patients. (A) Overall concordant copy number status
between the two biopsies does not provide evidence of distinct founding clones. GS = 3 + 4 core has pattern 4 with fused and cribriform morphology.
(B) Different genomic copy number status of the genomic region encompassing ERG to TMPRSS2 genes (21q22.2), both clonal, is observed, suggesting
the presence of two distinct clones. GS = 3 + 4 core has pattern 4 cribriform morphology. (C) Both GS = 3 + 3 cores available for patient 17 show
concordant genomic profiles suggesting the same origin. Conversely, core GS = 3 + 4 (having pattern 4 fused and cribriform morphology) differs from
both GS = 3 + 3 cores in the genomic status of PTEN (loss in GS = 3 + 3 cores, copy number normal in GS = 3 + 4 core) and MYC (copy number normal in
GS = 3 + 3 cores, gain in GS = 3 + 4 core). This suggests the presence of a different clone.
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somatic changes but clear evidence of a few aberrations,
includingNKX3-1 deletion. Given the incidence of such copy
number loss in localized disease, we can neither suggest nor
exclude distinct founding clones between the GS = 3 + 3 and
3 + 4 cores. In contrast, patient 11 demonstrated different
and highly clonal genomic copy number status of the region
encompassing ERG to TMPRSS2 genes (21q22.2), suggesting
two distinct clones between the cores [16].
Finally, both GS = 3 + 3 cores available for patient
17 showed concordant genomic profiles with multiple
aberrations, whereas the GS = 3 + 4 core differed from both
GS = 3 + 3 foci in the genomic status of PTEN (loss in GS = 3
+ 3 cores, normal copy number in GS = 3 + 4 core) and MYC
(normal copy number in GS = 3 + 3 cores, gain in GS = 3
+ 4 core). This latter patient’s data are suggestive of distinct
clonal origin of the GS = 3 + 4 clone with respect to GS = 3
+ 3.4. Discussion
Management options for men with low-grade PCa include
AS as a noninvasive alternative to radical treatment. AS
enrollment criteria rely primarily on biopsy pathological
characteristics; however, due to biopsy sampling, subjec-
tivity of grading or tumor progression, upgrading, or
upstaging is observed in 25% of cases [3,4]. Molecular
biomarkers to be eventually assessed on bioptic coresmight
aid enrollment criteria overall. Genomic features enriched
in higher GS tumors or associated with worse prognosis and
disease progression in large cohorts of PCa patients and
prostatectomy series could serve as AS protocol exclusion
indicators and potentially spot lethal clones [19].
Prostatectomy-based studies focused on the characteriza-
tion of somatic genomic lesions along the exome showed that
G3 tumors can retain their indolent-appearing morphology
despite the acquisition of multiple genomic alterations [7–
E U RO P E AN U RO L OGY ONCO L OGY 2 ( 2 019 ) 2 7 7 – 2 8 52849]. Whether GS = 3 + 3 cores of patients who upgrade to
GS> 3 + 3 during follow-up harbor a distinct genomic profile
to men who continue on AS has not yet been investigated,
partly due to the ethical and legal hurdles inherent in the
analysisof these tumorsandthetechnical challengesrelated to
the scant availablematerial. To the best of our knowledge, our
study is indeed the first unbiased characterization of the
genomic landscapeof low-gradePCapatients inAS. To analyze
a collection of tumors that is representative of the clinical
routine, we included samples that span a wide range of
pathology-based cellularity, from 5% to 90% (Supplementary
Table 2). WES data successfully generated from nonindolent
and potentially indolent biopsies demonstrated that >1/3 of
GS = 3 + 3/PGG1 tumors have non-flat genomes, irrespective
of the class. Given the experimental design including high
sequencing coverage (>200 for tumors) and full exome
(40 Mb), we exclude that the observed flat genomes are
entirelyascribable to lowcellularityof bioptic cores, but rather
represent true biologically flat genomes. Cases with compara-
ble pathological cellularity assessment, below 40%, indeed led
to detectable lesions. Overall, the fraction of GS = 3 + 3 cores
withnoevidenceof SCNAs (66%) is slightly higher thanwhat is
observed in Gleason 6 tumors from The Cancer Genome Atlas
(TCGA) prostatectomy collection [16].
When focusing on genomic lesions enriched in meta-
static disease [20] and associated with disease recurrence
upon prostatectomy, includingMYC amplification and PTEN
loss, all but onewere detected in the GS = 3 + 3 core biopsies
of nonindolent patients. The allele-specific multisample
analyses performed on selected patients to compare GS = 3
+ 3/PGG1with the upgrading GS = 3 + 4/PGG2 core included
evidence both for common (patient 11) and distinct clonal
origin (patient 17), concordant with the observations from
Boutrous and colleagues [21] reporting on spatial genomic
heterogeneity of localized multifocal PCa.
Overall, these data demonstrate that genomic characteri-
zation of bioptic material from AS patients, despite being
challenging, provides insights towards the sampling versus
‘tumor evolution’ explanation of upgrading. Althoughdescrip-
tive in nature (more qualitative than quantitative), this study
represents a proof-of-concept of the feasibility of performing
large-scale genomic analysis from challenging biopsies with
low percentages of tumor positivity. The main limitations are
the retrospective analysis (though on prospectively collected
material) and the limited cohort size. As we opted for large-
scale genomics (WESof biopsyDNA), the latterwasdecidedby
availability of at least two tumor biopsies, which shortlisted
54 from>300 enrolled AS patients. Our results suggest that a
well-designed targeted next-generation sequencing assay—
for which DNA extracted from biopsy slides could be
sufficient—to profile a large collection of AS patients should
help unravel the true determinants of dropouts, which could
then be considered for patient exclusion from or more strict
monitoring during AS..
5. Conclusions
Although exhaustive molecular characterization of positive
biopsies is not feasible for all AS patients due to insufficienttumor material, here we showed that MYC amplification
and PTEN deletion detected by WES were confirmed by
immunohistochemistry. Due to the limited sample size, the
role of PTEN deletion and MYC amplification should be
further investigated in larger cohorts of AS patients to
understand if they can represent biomarkers for a more
precise and earlier identification of patients at risk of
reclassification/progression prior to the manifestation of
conventional pathological markers.
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